Inovio Pharmaceuticals, Inc.
GBMB.F
Get informed when a big investor buys or sells
+ FollowMarket Cap$79.46M
Close$
Share Statistics
| Market cap | $79.46 Million |
|---|---|
| Enterprise Value | $55.93 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.5 |
| Beta | 0.95 |
| Outstanding Shares | 268,622,753 |
Return
| Return on Equity | -1942959.72% |
|---|---|
| Return on Assets | -171956.37% |
| Return on Invested Capital | -916221.94% |
Valuation & Multiples
| P/E Ratio | -0.99 |
|---|---|
| PEG | 1.33 |
| Price to Sales | -0.55 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -855.97 |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 1.83 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Inovio Pharmaceuticals Inc
112 employees
CEO: Jong Kim Inovio Pharmaceuticals, Inc. is a biotechnology firm focused on researching, developing, and bringing to market DNA-based treatments designed to address and safeguard individuals from conditions linked to human papillomavirus (HPV), vari...